Camber launches mycophenolate mofetil tablets

Camber has introduced mycophenolate mofetil tablets, which are the generic of CellCept, further expanding its immunosuppressant portfolio following the April 2025 launch of mycophenolate mofetil capsules. 

Camber said that with more than 48,000 organ transplants performed annually in the United States—and more than 100,000 patients still on waiting lists—the company remains committed to providing critical therapies that support long-term organ acceptance and improve transplant outcomes.

[Read more: Camber touts 13 generic launches in Q1 2025]

Mycophenolate mofetil (tablets) is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

Mycophenolate mofetil tablets are available in 500-mg strength, packaged in bottles of 100 and 500 tablets.